X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (293) 293
drug combinations (219) 219
female (212) 212
male (212) 212
albuterol - analogs & derivatives (211) 211
fluticasone-salmeterol drug combination (200) 200
index medicus (195) 195
middle aged (176) 176
administration, inhalation (169) 169
asthma - drug therapy (160) 160
androstadienes - administration & dosage (144) 144
albuterol - administration & dosage (138) 138
adult (136) 136
respiratory system (135) 135
salmeterol (135) 135
asthma (132) 132
aged (128) 128
bronchodilator agents - administration & dosage (127) 127
fluticasone (126) 126
androstadienes - therapeutic use (120) 120
treatment outcome (120) 120
albuterol - therapeutic use (118) 118
pulmonary disease, chronic obstructive - drug therapy (110) 110
double-blind method (82) 82
bronchodilator agents - therapeutic use (79) 79
fluticasone propionate (79) 79
adolescent (69) 69
fluticasone-salmeterol drug combination - administration & dosage (64) 64
drug therapy, combination (59) 59
copd (58) 58
pharmacology & pharmacy (56) 56
drug therapy (55) 55
obstructive pulmonary-disease (53) 53
asthma - physiopathology (52) 52
young adult (52) 52
inhaled corticosteroids (51) 51
androstadienes - adverse effects (50) 50
glucocorticoids - administration & dosage (50) 50
exacerbations (49) 49
albuterol - adverse effects (47) 47
child (47) 47
corticosteroids (47) 47
lung diseases, obstructive (47) 47
adrenal cortex hormones - administration & dosage (46) 46
bronchodilator agents - adverse effects (46) 46
formoterol fumarate (45) 45
salmeterol xinafoate (45) 45
adrenergic beta-2 receptor agonists - administration & dosage (44) 44
anti-asthmatic agents - administration & dosage (44) 44
ethanolamines - administration & dosage (44) 44
pulmonary disease, chronic obstructive - physiopathology (44) 44
allergy (43) 43
chronic obstructive pulmonary disease (43) 43
dosage and administration (43) 43
forced expiratory volume (43) 43
nebulizers and vaporizers (43) 43
pulmonary/respiratory (43) 43
research (43) 43
glucocorticoids - therapeutic use (42) 42
formoterol (40) 40
pulmonary and respiratory medicine (38) 38
time factors (38) 38
severity of illness index (37) 37
aged, 80 and over (35) 35
anti-asthmatic agents - therapeutic use (35) 35
cross-over studies (35) 35
metered dose inhalers (35) 35
respiratory function tests (35) 35
care and treatment (34) 34
ethanolamines - therapeutic use (34) 34
budesonide - administration & dosage (33) 33
double-blind (31) 31
fluticasone-salmeterol drug combination - therapeutic use (31) 31
forced expiratory volume - drug effects (31) 31
lung - drug effects (31) 31
combination (30) 30
lung - physiopathology (30) 30
budesonide (29) 29
respiratory tract diseases (29) 29
retrospective studies (29) 29
diseases of the respiratory system (28) 28
propionate (28) 28
quality of life (28) 28
budesonide - therapeutic use (27) 27
disease progression (27) 27
fluticasone-salmeterol drug combination - adverse effects (27) 27
pulmonary disease, chronic obstructive - diagnosis (27) 27
steroids (27) 27
abridged index medicus (26) 26
adrenal cortex hormones - therapeutic use (26) 26
drug administration schedule (26) 26
adrenergic beta-agonists - administration & dosage (25) 25
cardiac & cardiovascular systems (25) 25
dry powder inhalers (25) 25
metered-dose inhaler (25) 25
safety (25) 25
salmeterol/fluticasone propionate (25) 25
albuterol - economics (24) 24
androstadienes - economics (24) 24
analysis (23) 23
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (288) 288
Japanese (9) 9
Chinese (5) 5
French (3) 3
Dutch (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 9, pp. 840 - 849
Journal Article
Journal Article
Journal Article
Respiratory Research, ISSN 1465-9921, 02/2015, Volume 16, Issue 1, pp. 25 - 25
Background: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled corticosteroid (ICS)/long-acting beta(2) agonist (LABA) treatment... 
Vilanterol | Mixed treatment comparison | ICS/LABA | Network meta-analysis | Fluticasone furoate | COPD | MODERATE | METAANALYSIS | SAFETY | MU-G | LUNG-FUNCTION | SALMETEROL | PROPIONATE | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | DOUBLE-BLIND | PROPIONATE/SALMETEROL | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Benzyl Alcohols - administration & dosage | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Recovery of Function | Chlorobenzenes - administration & dosage | Forced Expiratory Volume | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Female | Bronchodilator Agents - adverse effects | Pulmonary Disease, Chronic Obstructive - diagnosis | Drug Administration Schedule | Risk Factors | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Disease Progression | Fluticasone-Salmeterol Drug Combination - administration & dosage | Randomized Controlled Trials as Topic | Adrenal Cortex Hormones - adverse effects | Androstadienes - administration & dosage | Chlorobenzenes - adverse effects | Lung - drug effects | Bayes Theorem | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Androstadienes - adverse effects | Budesonide, Formoterol Fumarate Drug Combination - administration & dosage | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Research | Drug therapy | Steroids | LABA | ICS
Journal Article
Medicine (United States), ISSN 0025-7974, 2015, Volume 94, Issue 51, p. e2306
A combination of long-acting anticholinergic agents (LAACs) and long-acting beta(2)-adrenergic receptor agonist (LABA) is effective in improving lung function... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | EFFICACY | INFLAMMATION | EXACERBATIONS | TIOTROPIUM | ANTICHOLINERGICS | FIXED-DOSE COMBINATION | CARDIOVASCULAR SAFETY | GLYCOPYRRONIUM | SALMETEROL | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Salmeterol Xinafoate - adverse effects | Fluticasone-Salmeterol Drug Combination - adverse effects | Stroke - chemically induced | Tiotropium Bromide - administration & dosage | Adrenergic beta-Agonists - administration & dosage | Aged, 80 and over | Female | Bronchodilator Agents - adverse effects | Cholinergic Antagonists - adverse effects | Adrenergic beta-Agonists - adverse effects | Tiotropium Bromide - adverse effects | Formoterol Fumarate - adverse effects | Administration, Inhalation | Salmeterol Xinafoate - administration & dosage | Cholinergic Antagonists - administration & dosage | Fluticasone-Salmeterol Drug Combination - administration & dosage | Budesonide, Formoterol Fumarate Drug Combination - adverse effects | Taiwan - epidemiology | Aged | Cardiovascular Diseases - chemically induced | Delayed-Action Preparations | Budesonide, Formoterol Fumarate Drug Combination - administration & dosage | Drug Combinations | Cohort Studies | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Usage | Cohort analysis | Research | Risk factors | Bronchodilator agents | Morbidity
Journal Article
Respiratory Medicine, ISSN 0954-6111, 08/2017, Volume 129, pp. 199 - 206
Asthma has a substantial impact on quality of life and health care resources. The identification of a more cost-effective, yet equally efficacious, treatment... 
Fixed-dose combination inhalers | Formoterol | GINA | Cost-effectiveness | Real-life | Asthma | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | EFFICACY | OPEN-LABEL | BUDESONIDE/FORMOTEROL | SALMETEROL | ASTHMA CONTROL | THERAPY | RESPIRATORY SYSTEM | DISEASE | INSIGHTS | Androstadienes - economics | Anti-Asthmatic Agents - therapeutic use | Humans | Middle Aged | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Ethanolamines - administration & dosage | Asthma - economics | Adult | Female | Cost-Benefit Analysis - economics | Anti-Asthmatic Agents - economics | Treatment Outcome | Ethanolamines - economics | Patient Acceptance of Health Care - statistics & numerical data | Asthma - drug therapy | Fluticasone-Salmeterol Drug Combination - administration & dosage | Drug Therapy, Combination - methods | Androstadienes - administration & dosage | Fluticasone-Salmeterol Drug Combination - economics | Quality of Life | Ethanolamines - therapeutic use | Aged | Androstadienes - therapeutic use | United Kingdom - epidemiology | Drug Combinations | Cohort Studies | Evaluation | Analysis | Pharmacy | Salmeterol | Drugstores | Dosage and administration | Research institutes | Drug therapy, Combination | Steroids | Medical care, Cost of | Health care | Therapy | Costs | Health services | Propionic acid | Fluticasone | Patients | Data bases | Impact analysis | Quality of life | Confidence intervals | Studies | Databases | Chronic obstructive pulmonary disease | Cost analysis | Drug therapy | Drug dosages | Cost engineering
Journal Article